SCHEMBL16100307

SCHEMBL16100307

CC(C)(C)NC1CCN(c2cc(-c3ccc(Cl)cc3)nc3ccccc23)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MOK Q9UQ07 1/20 0.47
ACP1 P24666 1/20 0.43
METAP1 P53582 2/20 0.43
MAPK1 P28482 3/20 0.43
POLB P06746 1/20 0.43
ATM Q13315 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16098063 0.99 L3MBTL1 (0.51) L3MBTL1KDM4EMOKACP1METAP1
Hydrochloric Acid SCHEMBL16098734 0.99 L3MBTL1 (0.51) L3MBTL1KDM4EMOKACP1METAP1
SCHEMBL16096541 0.92 KDM4E (0.61) L3MBTL1KDM4EMOKMETAP1MAPK1
Hydrochloric Acid SCHEMBL16101548 0.91 KDM4E (0.60) L3MBTL1KDM4EMOKMETAP1MAPK1
Hydrochloric Acid SCHEMBL16096749 0.91 KDM4E (0.60) L3MBTL1KDM4EMOKMETAP1MAPK1
SCHEMBL16097530 0.90 KDM4E (0.53) L3MBTL1KDM4EMOKACP1METAP1
SCHEMBL16101302 0.90 METAP1 (0.48) L3MBTL1KDM4EMOKACP1METAP1
Hydrochloric Acid SCHEMBL16101534 0.89 KDM4E (0.52) L3MBTL1KDM4EMOKMETAP1POLB
Hydrochloric Acid SCHEMBL16098155 0.89 KDM4E (0.52) L3MBTL1KDM4EMOKMETAP1POLB
Hydrochloric Acid SCHEMBL16101939 0.89 METAP1 (0.47) L3MBTL1KDM4EMOKACP1METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10179770-B2 Quinolines derivatives as novel anticancer agents GENOSCIENCE PHARMA (FR) 2019-01-15 US claimed
EP-2976333-B1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA SAS (FR) 2018-08-08 EP claimed
US-20160280653-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA (FR) 2016-09-29 US claimed
EP-2976333-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS Genoscience Pharma SAS (FR) 2016-01-27 EP claimed
WO-2014147611-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA (FR) 2014-09-25 WO claimed
US-10179770-B2 Quinolines derivatives as novel anticancer agents GENOSCIENCE PHARMA (FR) 2019-01-15 US disclosed
US-10179770-B2 Quinolines derivatives as novel anticancer agents GENOSCIENCE PHARMA (FR) 2019-01-15 US disclosed
EP-2976333-B1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA SAS (FR) 2018-08-08 EP disclosed
EP-2976333-B1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA SAS (FR) 2018-08-08 EP disclosed
US-20160280653-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA (FR) 2016-09-29 US disclosed
US-20160280653-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA (FR) 2016-09-29 US disclosed
US-20160280653-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA (FR) 2016-09-29 US disclosed
EP-2976333-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS Genoscience Pharma SAS (FR) 2016-01-27 EP disclosed
WO-2014147611-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA (FR) 2014-09-25 WO disclosed
WO-2014147611-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA (FR) 2014-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10179770-B2 Quinolines derivatives as novel anticancer agents NQO2, MKI67, NQO1 L3MBTL1 3884/4885KDM4E 979/4885MOK 4634/4885
US-20160280653-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS NQO2, MKI67, NQO1 L3MBTL1 3884/4885KDM4E 979/4885MOK 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.